Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dexmethylphenidate hydrochloride
Drug ID BADD_D00631
Description Dexmethylphenidate is the dextrorotary form of methylphenidate introduced in 2002[A177181]. It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant[A177193]. It is used for treatment of Attention Deficit Hyperactivity Disorder (ADHD)[Label,A177181]. The d-isomer is thought to have greater effect with fewer side effects than the l-isomer or the racemic mixture[A177181].
Indications and Usage Dexmethylphenidate is used as a treatment for ADHD, ideally in conjunction with psychological, educational, behavioral or other forms of treatment[A177187,Label].
Marketing Status approved; investigational
ATC Code N06BA11
DrugBank ID DB06701
KEGG ID D03721
MeSH ID D064699
PubChem ID 154100
TTD Drug ID D02QCD
NDC Product Code 0781-2686; 11014-0316; 60274-710; 0078-0382; 0115-1684; 43602-332; 43602-333; 49884-048; 49884-539; 57664-379; 57664-622; 57664-624; 70010-009; 0527-8106; 0781-2688; 10702-108; 16714-567; 27808-091; 27808-093; 0115-1682; 42858-225; 43386-862; 43602-327; 57664-626; 63629-2175; 63629-2177; 63629-9469; 70010-005; 72162-1472; 72162-1503; 0781-2687; 11014-0314; 60274-720; 10702-107; 0078-0381; 0078-0431; 0078-0432; 0078-0433; 0093-5562; 42858-410; 43602-330; 43602-331; 57664-378; 63629-2173; 63629-2174; 70010-008; 70010-010; 70010-011; 57664-629; 0527-8109; 0527-8110; 0527-8111; 72162-1502; 53834-201; 0078-0609; 16714-566; 0093-5046; 0093-5553; 27808-092; 31722-229; 0115-1683; 0115-1685; 0115-1709; 49884-090; 57664-376; 57664-625; 72162-1493; 0781-2684; 11014-0080; 11014-0211; 11014-0213; 31722-234; 31722-236; 49884-248; 63629-2176; 63629-2178; 63629-2306; 63629-2307; 67877-655; 67877-656; 70010-007; 0527-8113; 72162-1473; 72162-1507; 0781-2683; 0781-2685; 60274-730; 16714-568; 43602-334; 57664-628; 63629-2172; 63629-9467; 70010-006; 0527-8108; 72162-1496; 11014-0103; 11014-0212; 60274-705; 0078-0434; 0078-0493; 0093-5550; 0115-9918; 0115-9920; 42858-011; 43602-328; 49884-333; 67877-657; 0527-8107; 0781-2682; 0781-2689; 17180-1725; 0078-0380; 0078-0430; 0093-5552; 0115-9921; 0115-9922; 43386-861; 43602-329; 49884-339; 49884-546; 57664-623; 63629-2305; 70010-004; 11014-0317; 10702-106; 16714-562; 0093-5045; 31722-230; 31722-233; 0115-1686; 0115-1710; 0115-9919; 43386-860; 63629-2171; 63629-9468; 0527-8112; 72162-1488; 0792-0619; 11014-0315; 11014-0318; 60274-715; 60274-725; 60274-735; 60274-740; 0078-0608; 16714-563; 16714-564; 16714-565; 16714-569; 0093-5551; 0093-5554; 31722-231; 31722-232; 31722-235; 49884-049; 57664-621
UNII 1678OK0E08
Synonyms Dexmethylphenidate Hydrochloride | Hydrochloride, Dexmethylphenidate | Focalin XR | XR, Focalin | Dexmethylphenidate | Focalin
Chemical Information
Molecular Formula C14H20ClNO2
CAS Registry Number 19262-68-1
SMILES COC(=O)C(C1CCCCN1)C2=CC=CC=C2.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypersensitivity10.01.03.003--
Immune system disorder10.02.01.001---
Insomnia17.15.03.002; 19.02.01.002--
Irritability08.01.03.011; 19.04.02.013--
Laryngeal pain22.12.03.010--
Leukopenia01.02.02.001---
Mood swings19.04.03.001---
Muscle twitching15.05.03.005---
Nasal congestion22.04.04.001--
Nausea07.01.07.001--
Nervous system disorder17.02.10.001---
Nervousness19.06.02.003---
Neuroleptic malignant syndrome08.05.01.005; 12.03.01.003; 15.05.04.015; 17.05.02.003---
Palpitations02.11.04.012--
Priapism21.03.01.005; 24.04.12.007---
Pruritus23.03.12.001--
Rash23.03.13.001---
Somnolence17.02.04.006; 19.02.05.003--
Tachycardia02.03.02.007---
Thrombocytopenic purpura01.08.01.003; 23.06.01.007---
Tourette's disorder03.10.01.001; 17.19.02.001; 19.11.04.002---
Urticaria10.01.06.001; 23.04.02.001--
Vasculitis necrotising10.02.02.008; 24.12.04.029---
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Musculoskeletal discomfort15.03.04.001---
Affect lability19.04.01.001---
Malnutrition14.03.02.004---
Mediastinal disorder22.09.03.001---
Mental disorder19.07.01.002---
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages